Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS (C-AXSPAND)

• ClinicalTrials.gov Identifier: NCT02552212
• Recruitment Status: Completed
• First Posted: September 17, 2015
• Results First Posted: August 17, 2020
• Last Update Posted: August 18, 2022
• Sponsor: UCB BIOSCIENCES GmbH
• Information provided by (Responsible Party): UCB Pharma ( UCB BIOSCIENCES GmbH )

Study Description

Brief Summary:

Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis and with signs of inflammation will be randomly assigned to receive certolizumab pegol (CZP) 200 mg every two weeks or placebo. The primary objective is to demonstrate the efficacy of CZP in these patients.

Condition or disease	Intervention/treatment	Phase
Axial Spondyloarthritis; Nonradiographic Axial Spondyloarthritis; Nr-axSpA	Biological: Certolizumab Pegol; Other: Placebo	Phase 3

Expanded Access : An investigational treatment associated with this study is available outside the clinical trial.   More info ...

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 317 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
• Actual Study Start Date: September 2015
• Actual Primary Completion Date: May 2018
• Actual Study Completion Date: May 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: Certolizumab Pegol 200 mg Q2W; Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.	Biological: Certolizumab Pegol; Active Substance: Certolizumab Pegol; Pharmaceutical Form: Prefilled syringe; Concentration: 200 mg / ml; Route of Administration: Subcutaneous injection; Other Names: Cimzia; CDP870
Placebo Comparator: Placebo; Matching placebo to Certolizumab Pegol (CZP) injections are administered every 2 weeks from Week 0 onwards.	Other: Placebo; Active Substance: Placebo; Pharmaceutical Form: Prefilled syringe; Concentration: 0.9 % saline; Route of Administration: Subcutaneous injection

Outcome Measures

Primary Outcome Measures :

1. Percentage of Subjects With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) Response Criteria Response at Week 52 [ Time Frame: Week 52 ]

   This variable was considered as primary in all countries except for Canada (and any other country where applicable or where requested by Regulatory Authorities) where it was considered as secondary variable.

   ASDAS-MI was achieved when there was a reduction (improvement) >= 2.0 in the ASDAS relative to Baseline, or when the lowest possible ASDAS score (0.6) was reached.

   The ASDAS was calculated as the sum of the following components:

   0.121 × Back pain (BASDAI Q2 result) 0.058 × Duration of morning stiffness (BASDAI Q6 result) 0.110 × Patient's Global Assessment of Disease Activity (PGADA) 0.073 × Peripheral pain/swelling (BASDAI Q3 result) 0.579 × (natural logarithm [ln] of the (CRP [mg/L] + 1)) Back pain, PGADA, duration of morning stiffness, peripheral pain/swelling and fatigue were all assessed on a numerical scale (0 to 10 units, where 0 is "not active" and 10 is "very active").

2. Percentage of Subjects With Axial SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 12 [ Time Frame: Week 12 ]

   This variable was considered as primary for Canada (and any other country where applicable or where requested by Regulatory Authorities) and as secondary variable in all other countries.

   The ASAS40 response was defined as relative improvements of at least 40 % and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS), where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: Patient's Global Assessment of Disease Activity (PGADA), Pain assessment (total spinal pain NRS scores), Function (Bath Ankylosing Spondylitis Functional Index (BASFI), Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)) questions 5 and 6 concerning morning stiffness intensity and duration) and no worsening at all in the remaining domain.

3. Certolizumab Pegol Plasma Concentration at Baseline [ Time Frame: Baseline (Week 0) ]
   Certolizumab pegol plasma concentration was measured at Baseline in micrograms per millilitre (µg/mL).
4. Certolizumab Pegol Plasma Concentration at Week 1 [ Time Frame: Week 1 ]
   Certolizumab pegol plasma concentration was measured at Week 1, in µg/mL.
5. Certolizumab Pegol Plasma Concentration at Week 2 [ Time Frame: Week 2 ]
   Certolizumab pegol plasma concentration was measured at Week 2, in µg/mL.
6. Certolizumab Pegol Plasma Concentration at Week 4 [ Time Frame: Week 4 ]
   Certolizumab pegol plasma concentration was measured at Week 4, in µg/mL.
7. Certolizumab Pegol Plasma Concentration at Week 12 [ Time Frame: Week 12 ]
   Certolizumab pegol plasma concentration was measured at Week 12, in µg/mL.
8. Certolizumab Pegol Plasma Concentration at Week 24 [ Time Frame: Week 24 ]
   Certolizumab pegol plasma concentration was measured at Week 24, in µg/mL.
9. Certolizumab Pegol Plasma Concentration at Week 36 [ Time Frame: Week 36 ]
   Certolizumab pegol plasma concentration was measured at Week 36, in µg/mL.
10. Certolizumab Pegol Plasma Concentration at Week 52 [ Time Frame: Week 52 ]
    Certolizumab pegol plasma concentration was measured at Week 52, in µg/mL.
11. Certolizumab Pegol Plasma Concentration at Follow-Up (FU) Visit [ Time Frame: Follow-up Visit (up to Week 60) ]

    Certolizumab pegol plasma concentration was measured at the Follow-Up Visit, in µg/mL.

    Follow-Up Visit was defined as 8 weeks after Week 52 or Withdrawal (WD) visit for subjects not participating in the Safety Follow-Up Extension (SFE) Period.

Secondary Outcome Measures :

1. Percentage of Subjects With Axial SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 52 [ Time Frame: Week 52 ]
   The ASAS40 response was defined as relative improvements of at least 40% and absolute improvement of at least 2 units on a 0 to 10 Numeric Rating Scale (NRS), where 0 is "not active" and 10 is "very active" in at least 3 of the 4 domains: Patient's Global Assessment of Disease Activity (PGADA), Pain assessment (total spinal pain NRS scores), Function (Bath Ankylosing Spondylitis Functional Index (BASFI)), Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)) questions 5 and 6 concerning morning stiffness intensity and duration) and no worsening at all in the remaining domain.
2. Change From Baseline to Week 12 in the Bath Ankylosing Spondylitis Functional Index (BASFI) [ Time Frame: From Baseline to Week 12 ]
   The BASFI is a validated disease-specific instrument for assessing physical function. The BASFI comprises 10 items relating to the past week. The BASFI is the mean of the 10 scores such that the total score ranges from 0 (Easy) to 10 (Impossible), with lower scores indicating better physical function. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
3. Change From Baseline to Week 52 in the Bath Ankylosing Spondylitis Functional Index (BASFI) [ Time Frame: From Baseline to Week 52 ]
   The BASFI is a validated disease-specific instrument for assessing physical function. The BASFI comprises 10 items relating to the past week. The BASFI is the mean of the 10 scores such that the total score ranges from 0 (Easy) to 10 (Impossible), with lower scores indicating better physical function. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
4. Change From Baseline to Week 12 in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [ Time Frame: From Baseline to Week 12 ]
   The BASDAI is a validated self-reported instrument, which consists of six 10 unit horizontal Numeric Rating Scales to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI scores ranges from 0 (not active) to 10 (very active), with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
5. Change From Baseline to Week 52 in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [ Time Frame: From Baseline to Week 52 ]
   The BASDAI is a validated self-reported instrument, which consists of six 10 unit horizontal Numeric Rating Scales to measure the disease activity of ankylosing spondylitis (AS) from the subject's perspective. It measures the severity of fatigue, spinal and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and duration) over the last week. The final BASDAI scores ranges from 0 (not active) to 10 (very active), with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
6. Change From Baseline to Week 12 in Sacroiliac Spondyloarthritis Research Consortium of Canada (SI-SPARCC) Score [ Time Frame: From Baseline to Week 12 ]
   The Spondyloarthritis Research Consortium of Canada (SPARCC) scoring method for lesions found on the Magnetic Resonance Imaging (MRI) is based on an abnormal increased signal on the Short-Tau-Inversion Recovery (STIR) sequence, representing bone marrow edema. Total Sacroiliac (SI) joint SPARCC score can range from 0 to 72 with higher scores indicating higher joint inflammation. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
7. Number of Subjects Without Relevant Changes to Background Medication From Baseline to Week 52 [ Time Frame: From Baseline to Week 52 ]

   The number of subjects who did not have relevant changes to background medications during the study treatment period.

   A subject is without relevant changes to background medication if they do not have: the addition of a new disease-modifying antirheumatic drug (DMARD) or the change from one DMAR to another; the addition of an nonsteroidal anti-inflammatory drug (NSAID) or the change from one NSAID to another; an increased dose of chronic corticosteroids; the addition of a new chronic analgesic medication or increased dose in chronic analgesic medication; and they complete double-blind study treatment to Week 52.

8. Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 52 [ Time Frame: From Baseline to Week 52 ]
   The ASQoL score ranged from 0 to 18 with higher score indicating worse Health-Related Quality of Life (HRQoL) and 0 indicating good HRQoL. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
9. Change From Baseline in ASQoL at Week 1 [ Time Frame: From Baseline to Week 1 ]
   The ASQoL score ranged from 0 to 18 with higher score indicating worse Health-Related Quality of Life (HRQoL) and 0 indicating good HRQoL. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
10. Change From Baseline in ASQoL at Week 2 [ Time Frame: From Baseline to Week 2 ]
    The ASQoL score ranged from 0 to 18 with higher score indicating worse Health-Related Quality of Life (HRQoL) and 0 indicating good HRQoL. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
11. Change From Baseline in ASQoL at Week 4 [ Time Frame: From Baseline to Week 4 ]
    The ASQoL score ranged from 0 to 18 with higher score indicating worse Health-Related Quality of Life (HRQoL) and 0 indicating good HRQoL. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
12. Change From Baseline in ASQoL at Week 12 [ Time Frame: From Baseline to Week 12 ]
    The ASQoL score ranged from 0 to 18 with higher score indicating worse Health-Related Quality of Life (HRQoL) and 0 indicating good HRQoL. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
13. Change From Baseline in ASQoL at Week 24 [ Time Frame: From Baseline to Week 24 ]
    The ASQoL score ranged from 0 to 18 with higher score indicating worse Health-Related Quality of Life (HRQoL) and 0 indicating good HRQoL. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
14. Change From Baseline in ASQoL at Week 36 [ Time Frame: From Baseline to Week 36 ]
    The ASQoL score ranged from 0 to 18 with higher score indicating worse Health-Related Quality of Life (HRQoL) and 0 indicating good HRQoL. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
15. Change From Baseline in ASQoL at Week 48 [ Time Frame: From Baseline to Week 48 ]
    The ASQoL score ranged from 0 to 18 with higher score indicating worse Health-Related Quality of Life (HRQoL) and 0 indicating good HRQoL. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
16. Change From Baseline in Nocturnal Spinal Pain Numerical Rating Scale (NRS) at Week 52 [ Time Frame: From Baseline to Week 52 ]
    The nocturnal spinal pain experienced by subjects due to AS was measured by following question 'How much pain of your spine due to spondylitis do you have at night?'. The NRS ranged from 0 to 10, where 0 represented 'no pain' and 10 represented 'most severe pain'. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.
17. Number of Subjects With Anterior Uveitis (AU) or New AU Flares Through Week 52 [ Time Frame: Throughout the study conduct (up to Week 52) ]
    The number of subjects with AU or new AU flares during the study treatment period.
18. Percentage of Subjects With Treatment-Emergent Adverse Events (TEAEs) During the Study [ Time Frame: From Baseline up to the End of Safety Follow-up Extension Period (up to Week 156) ]
    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
19. Percentage of Subjects With Serious Adverse Events (SAEs) During the Study [ Time Frame: From Baseline up to the End of Safety Follow-up Extension Period (up to Week 156) ]

    A serious adverse event (SAE) is any untoward medical occurrence that at any dose:

    • Results in death
    • Is life-threatening
    • Requires in patient hospitalization or prolongation of existing hospitalization
    • Is a congenital anomaly or birth defect
    • Is an infection that requires treatment parenteral antibiotics
    • Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above.
20. Percentage of Subjects With Adverse Events Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study [ Time Frame: From Baseline up to the End of Safety Follow-up Extension Period (up to Week 156) ]
    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• At least 18 years old at the start of Screening Visit
• A documented diagnosis of adult-onset axial SpondyloArthritis (axSpA) and meet the Assessment of SpondyloArthritis International Society (ASAS) criteria for axSpA
• Subjects must have had back pain for at least 12 months before Screening
• No sacroiliitis defined by Modified New York (mNY) criteria on sacroiliac (SI) x-rays

• Active disease at Screening as defined by

  • Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score >= 4
  • Spinal pain >= 4 on a 0 to 10 Numerical Rating Scale (NRS)
• Inadequate response to, have a contraindication to, or have been intolerant to at least 2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Exclusion Criteria:

• Diagnosis of AS or any other Inflammatory Arthritis
• Prior treatment with any experimental biological agents for treatment of Axial SpondyloArthritis (SpA)
• Exposure to more than 1 tumor necrosis factor (TNF)-antagonist or primary failure to TNF antagonist therapy
• History of or current chronic or recurrent infections
• Subjects with known Tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent Tuberculosis (LTB)
• Recent live vaccination
• Concurrent malignancy or a history of malignancy
• Class III or IV congestive heart failure - New York Heart Association (NYHA)
• Demyelinating disease of the central nervous system
• Female subjects who are breastfeeding, pregnant or plan to become pregnant during the study or within 3 months following the last dose of the investigational product
• Subjects with any other condition which, in the investigator's judgment, would make the subject unsuitable for inclusion in the study

Contacts and Locations

Locations

United States, Alabama

As0006 125

Birmingham, Alabama, United States

United States, Arizona

As0006 120

Scottsdale, Arizona, United States

As0006 115

Tucson, Arizona, United States

United States, California

As0006 155

Beverly Hills, California, United States

As0006 101

Palm Desert, California, United States

As0006 143

San Francisco, California, United States

United States, Connecticut

As0006 160

New Haven, Connecticut, United States

United States, Florida

As0006 117

Daytona Beach, Florida, United States

As0006 116

DeBary, Florida, United States

As0006 124

Fort Lauderdale, Florida, United States

As0006 133

New Port Richey, Florida, United States

As0006 138

Plantation, Florida, United States

As0006 134

Tampa, Florida, United States

As0006 106

Vero Beach, Florida, United States

United States, Georgia

As0006 148

Atlanta, Georgia, United States

United States, Idaho

As0006 137

Idaho Falls, Idaho, United States

United States, Maryland

As0006 102

Cumberland, Maryland, United States

As0006 141

Cumberland, Maryland, United States

As0006 111

Wheaton, Maryland, United States

United States, Massachusetts

As0006 127

Boston, Massachusetts, United States

As0006 147

Worcester, Massachusetts, United States

United States, Minnesota

As0006 110

Eagan, Minnesota, United States

As0006 123

Rochester, Minnesota, United States

United States, Missouri

As0006 103

Saint Louis, Missouri, United States

United States, New York

As0006 114

Brooklyn, New York, United States

United States, North Carolina

As0006 118

Charlotte, North Carolina, United States

United States, Oklahoma

As0006 149

Oklahoma City, Oklahoma, United States

United States, Oregon

As0006 105

Portland, Oregon, United States

United States, Pennsylvania

As0006 108

Duncansville, Pennsylvania, United States

As0006 144

Philadelphia, Pennsylvania, United States

As0006 129

Wyomissing, Pennsylvania, United States

United States, South Carolina

As0006 156

Orangeburg, South Carolina, United States

United States, Utah

As0006 107

Salt Lake City, Utah, United States

United States, Washington

As0006 104

Seattle, Washington, United States

United States, Wisconsin

As0006 158

Manitowoc, Wisconsin, United States

As0006 113

Onalaska, Wisconsin, United States

Australia

As0006 208

Camperdown, Australia

As0006 210

Coffs Harbour, Australia

As0006 204

Footscray, Australia

As0006 201

Malvern East, Australia

As0006 209

Maroochydore, Australia

As0006 205

South Hobart, Australia

As0006 202

Victoria Park, Australia

Bulgaria

As0006 302

Plovdiv, Bulgaria

As0006 305

Plovdiv, Bulgaria

As0006 304

Ruse, Bulgaria

As0006 306

Sevlievo, Bulgaria

As0006 300

Sofia, Bulgaria

As0006 307

Sofia, Bulgaria

As0006 309

Sofia, Bulgaria

As0006 308

Varna, Bulgaria

Canada

As0006 152

Edmonton, Canada

As0006 150

Victoria, Canada

Czechia

As0006 326

Hlučín, Czechia

As0006 324

Hustopeče, Czechia

As0006 327

Olomouc, Czechia

As0006 320

Ostrava, Czechia

As0006 322

Pardubice, Czechia

As0006 328

Praha 2, Czechia

As0006 323

Praha, Czechia

As0006 329

Praha, Czechia

As0006 330

Praha, Czechia

As0006 333

Příbor, Czechia

As0006 332

Rychnov Nad Kněžnou, Czechia

As0006 331

Zlín, Czechia

Hungary

As0006 365

Balatonfüred, Hungary

As0006 362

Budapest, Hungary

As0006 363

Budapest, Hungary

As0006 361

Szekesfehervar, Hungary

Poland

As0006 406

Bydgoszcz, Poland

As0006 400

Elbląg, Poland

As0006 401

Kraków, Poland

As0006 402

Kraków, Poland

As0006 411

Lublin, Poland

As0006 403

Poznań, Poland

As0006 404

Poznań, Poland

As0006 405

Toruń, Poland

As0006 407

Warszawa, Poland

As0006 408

Warszawa, Poland

As0006 409

Warszawa, Poland

As0006 410

Warszawa, Poland

As0006 413

Wrocław, Poland

As0006 414

Wrocław, Poland

Russian Federation

As0006 461

Chelyabinsk, Russian Federation

As0006 453

Ivanovo, Russian Federation

As0006 450

Kazan, Russian Federation

As0006 451

Kazan, Russian Federation

As0006 458

Kemerovo, Russian Federation

As0006 455

Moscow, Russian Federation

As0006 466

Moscow, Russian Federation

As0006 462

Orenburg, Russian Federation

As0006 452

Ryazan', Russian Federation

As0006 459

Saint Petersburg, Russian Federation

As0006 463

Saint Petersburg, Russian Federation

As0006 464

Saint Petersburg, Russian Federation

As0006 467

Saint Petersburg, Russian Federation

As0006 465

Samara, Russian Federation

As0006 454

Saratov, Russian Federation

As0006 460

Smolensk, Russian Federation

As0006 456

Tolyatti, Russian Federation

As0006 457

Yaroslavl, Russian Federation

Taiwan

As0006 232

Hualien City, Taiwan

As0006 230

Taichung City, Taiwan

As0006 233

Taichung City, Taiwan

As0006 231

Taipei, Taiwan

Sponsors and Collaborators

UCB BIOSCIENCES GmbH

Investigators

• Study Director: UCB Cares; 1-844-599-2273 (UCB)

  Study Documents (Full-Text)

Documents provided by UCB Pharma ( UCB BIOSCIENCES GmbH ):

Study Protocol  [PDF] December 17, 2018

Statistical Analysis Plan  [PDF] June 10, 2020

More Information

Additional Information:

FDA Safety Alerts and Recalls 

Publications of Results:

van der Heijde D, Gensler LS, Maksymowych WP, Landewe R, Rudwaleit M, Bauer L, Kumke T, Kim M, Auteri SE, Hoepken B, Deodhar A. Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. RMD Open. 2022 Mar;8(1):e002138. doi: 10.1136/rmdopen-2021-002138.

Robinson PC, Maksymowych WP, Gensler LS, Hall S, Rudwaleit M, Hoepken B, Bauer L, Kumke T, Kim M, de Peyrecave N, Deodhar A. Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study. ACR Open Rheumatol. 2022 Sep;4(9):794-801. doi: 10.1002/acr2.11469. Epub 2022 Jun 22.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Maksymowych WP, Kumke T, Auteri SE, Hoepken B, Bauer L, Rudwaleit M. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol. Arthritis Res Ther. 2021 Oct 29;23(1):274. doi: 10.1186/s13075-021-02650-4.

Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landewe R, Rudwaleit M, Hall S, Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D. A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019 Jul;71(7):1101-1111. doi: 10.1002/art.40866. Epub 2019 May 28.

• Responsible Party: UCB BIOSCIENCES GmbH
• ClinicalTrials.gov Identifier: NCT02552212
• Other Study ID Numbers: AS0006; 2015-001894-41 ( EudraCT Number )
• First Posted: September 17, 2015
• Results First Posted: August 17, 2020
• Last Update Posted: August 18, 2022
• Last Verified: August 2022

Keywords provided by UCB Pharma ( UCB BIOSCIENCES GmbH ):

Axial Spondyloarthritis; axSpA; Ankylosing Spondylitis; Anti TNF-alpha; Certolizumab Pegol; Nr-axSpA; Non-radiographic; Spondylarthropathies; Arthritis; Spinal Diseases; Immunosuppressive Agents

Additional relevant MeSH terms:

Spondylitis; Spondylarthritis; Axial Spondyloarthritis; Non-Radiographic Axial Spondyloarthritis; Bone Diseases, Infectious; Infections; Bone Diseases; Musculoskeletal Diseases; Spinal Diseases; Spondylarthropathies; Ankylosis; Joint Diseases; Arthritis; Certolizumab Pegol; Tumor Necrosis Factor Inhibitors; Anti-Inflammatory Agents; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents